サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1074287

CFTRモジュレーターの世界市場 - 機会、薬剤売上、臨床試験に関する洞察：2028年

Global CFTR Modulators Market Opportunity, Drug Sales & Clinical Trials Insight 2028
出版日: | 発行: KuicK Research | ページ情報: 英文 150 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

CFTRモジュレーターの世界市場 - 機会、薬剤売上、臨床試験に関する洞察：2028年
出版日: 2022年05月01日
発行: KuicK Research
ページ情報: 英文 150 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要
当レポートでは、CFTRモジュレーター市場について調査し、市場の概要とともに、薬剤別の動向、パイプラインと臨床試験動向、将来の見通し、および市場に参入する企業の競合情勢などを提供しています。

目次

第1章 CFTRモジュレーターのイントロダクション

  • 概要
  • CFTRモジュレーターの進化
  • CFTRモジュレーターの作用機序

第2章 世界のCFTRモジュレーター市場概要

  • 現在の市場シナリオ
  • CFTRモジュレーターの将来の市場の可能性

第3章 米国のCFTRモジュレーター市場概要

  • 現在の市場シナリオ
  • CFTRモジュレーターの将来の市場の可能性

第4章 その他の地域のCFTRモジュレーター市場概要

  • 現在の市場シナリオ
  • CFTRモジュレーターの将来の市場の可能性

第5章 Ivacaftor （Kalydeco）-臨床および商業的洞察

第6章 Ivacaftor/Lumacaftor（Orkambi）-臨床および商業的洞察

第7章 Tezacaftor/Ivacaftor（Symdeko）-臨床および商業的洞察

第8章 Elexacaftor/Ivacaftor/Tezacaftor（Trikafta）-臨床および商業的洞察

第9章 世界のCFTRモジュレーター臨床パイプラインの概要

  • 国別
  • 企業別
  • 患者セグメント別
  • 相別

第10章 世界のCFTRモジュレーター臨床試験の洞察

  • 調査
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相

第11章 市販のCFTRモジュレーター臨床的洞察

第12章 CFTRモジュレーター薬市場力学

第13章 CFTRモジュレーター市場の将来展望

第14章 競合情勢

  • Vertex Pharmaceuticals
  • Eloxx Pharma
  • ReCode Therapeutics
  • Arcturus Therapeutics
  • AbbVie
  • Spirovant Sciences
  • Translate Bio
  • ReAlta Life Sciences
  • Southern Research Institute
  • 4D Molecular Therapeutics
図表

List of Figures

  • Figure 1-1: Different Approaches for CFTR Modulators
  • Figure 1-2: Classes of CFTR Protein Mutations
  • Figure 1-3: History of CFTR Modulators
  • Figure 1-4: CFTR Modulators - Specific Target for Different Approaches
  • Figure 2-1: Global - CFTR Modulator Drugs Market Size (US$ Million), 2017-2021
  • Figure 2-2: Global - CFTR Modulator Drugs Market Size by Product (US$ Million), 2020 & 2021
  • Figure 2-3: Global - CFTR Modulator Drugs Market Size by Product (%), 2021
  • Figure 2-4: Global - CFTR Modulator Drugs Market Size by Product (%), 2020
  • Figure 2-5: Global - CFTR Modulator Drugs Market (US$ Billion), 2022-2028
  • Figure 2-6: Global - Cystic Fibrosis Incidence, 2020-2026
  • Figure 3-1: US - Incidence of Cystic Fibrosis, 2010-2020
  • Figure 3-2: Global - CFTR Modulator Market Size by Region (US$ Billion), 2021
  • Figure 3-3: Global - CFTR Modulator Market Size by Region (%), 2021
  • Figure 3-4: US - Expected CFTR Modulator Drugs Market Size (US$ Billion), 2022 - 2028
  • Figure 3-5: US - Cystic Fibrosis Incidence, 2021-2026
  • Figure 4-1: Global - CFTR Modulator Market Size by Region (US$ Billion), 2021
  • Figure 4-2: Global - CFTR Modulator Market Size by Region (%), 2021
  • Figure 4-3: ROW - Expected CFTR Modulator Drugs Market Size (US$ Billion), 2020 - 2028
  • Figure 4-4: ROW - Cystic Fibrosis Incidence, 2020-2026
  • Figure 5-1: US - Kalydeco FDA Approval History
  • Figure 5-2: Europe - Kalydeco FDA Approval History
  • Figure 5-3: US- Kalydeco FDA Approval & Patent Expiration Year
  • Figure 5-4: Europe - Kalydeco FDA Approval & Patent Expiration Year
  • Figure 5-5: US - Kalydeco Patent Approval & Expiration Year
  • Figure 5-6: US - Cost of Supply of 56 Oral Granule & Per Unit Cost of Kalydeco Oral Granule (US$), May'2022
  • Figure 5-7: US - Cost of Supply of 56 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (US$), May'2022
  • Figure 5-8: Europe - Cost of Supply of 28 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (Eur/US$), May'2022
  • Figure 5-9: Europe - Cost of Supply of 56 Oral Tablet & Per Unit Cost of 50mg, 75mg & 150mg Kalydeco Oral Tablet (Eur/US$), May'2022
  • Figure 5-10: UK - Cost of Supply of 56 Oral Granules & Per Unit Cost of 25mg, 50mg & 75mg Kalydeco Oral Granules (GBP/US$), May'2022
  • Figure 5-11: UK - Cost of Supply of 56 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (GBP/US$), May'2022
  • Figure 5-12: UK - Cost of Supply of 28 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (GBP/US$), May'2022
  • Figure 5-13: Kalydeco - Recommended Pediatric Dose of Oral Granules for Cystic Fibrosis by Weight (mg/12hrs)
  • Figure 5-14: Kalydeco - Maximum Recommended Pediatric Dose for Cystic Fibrosis by Type (mg/12hrs)
  • Figure 5-15: Global - Kalydeco Sales (US$ Million), Q1'2021 & Q1'2022
  • Figure 5-16: Global - Kalydeco Annual Sales (US$ Million), 2017-2021
  • Figure 5-17: Global - Kalydeco Quarterly Sales (US$ Million), 2021
  • Figure 5-18: Global - Kalydeco Quarterly Sales (US$ Million), 2020
  • Figure 5-19: Global - Kalydeco Quarterly Sales (US$ Million), 2019
  • Figure 6-1: US - Orkambi FDA Approval History by Age
  • Figure 6-2: Europe - Orkambi FDA Approval History by Age
  • Figure 6-3: US- Orkambi FDA Approval & Patent Expiration Year
  • Figure 6-4: Europe - Orkambi FDA Approval & Patent Expiration Year
  • Figure 6-5: US - Orkambi Patent Approval & Expiration Year
  • Figure 6-6: US - Cost of Supply of 56 Oral Granule & Per Unit Cost of Orkambi Oral Granule (US$), May'2022
  • Figure 6-7: US - Cost of Supply of 112 Oral Tablet & Per Unit Cost of Orkambi Oral Tablet (US$), May'2022
  • Figure 6-8: Europe - Cost of Supply of 112 Oral Tablet & Per Unit Cost of Orkambi Oral Tablet (Euro/US$), May'2022
  • Figure 6-9: UK- Cost of Supply of 112 Oral Tablet & Per Unit Cost of Orkambi Oral Tablet (GBP/US$), May'2022
  • Figure 6-10: UK- Cost of Supply of 56 Oral Granules & Per Unit Cost of Orkambi Oral Granule (GBP/US$), May'2022
  • Figure 6-11: Orkambi - Recommended Dose by Age (mg/day)
  • Figure 6-12: Global - Orkambi Sales (US$ Million), Q1'2021 & Q1'2022
  • Figure 6-13: Global - Orkambi Annual Sales (US$ Million), 2017-2021
  • Figure 6-14: Global - Orkambi Quarterly Sales (US$ Million), 2021
  • Figure 6-15: Global - Orkambi Quarterly Sales (US$ Million), 2020
  • Figure 6-16: Global - Orkambi Quarterly Sales (US$ Million), 2019
  • Figure 7-1: US - Symdeko FDA Approval History by Age
  • Figure 7-2: Europe - Symdevi EU Approval History by Age
  • Figure 7-3: Europe - Symdevi Approval & Patent Expiration Year
  • Figure 7-4: US - Symdeko Approval & Patent Expiration Year
  • Figure 7-5: US - Symdeko Patent Approval & Expiration Year
  • Figure 7-6: US - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Symdeko Oral Tablet (US$), May'2022
  • Figure 7-7: Europe - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Symdeko Oral Tablet (Euro/US$), May'2022
  • Figure 7-8: Europe - Cost of Supply of 28 Oral Tablet & Per Unit Cost of Symkevi Oral Tablet (GBP/US$), May'2022
  • Figure 7-9: Global - Symdeko/Symkevi Sales (US$ Million), Q1'2021 & Q1'2022
  • Figure 7-10: Global - Symdeko/Symkevi Annual Sales (US$ Million), 2018-2021
  • Figure 7-11: Global - Symdeko/Symkevi Quarterly Sales (US$ Million), 2021
  • Figure 7-12: Global - Symdeko/Symkevi Quarterly Sales (US$ Million), 2020
  • Figure 7-13: Global - Symdeko/Symkevi Quarterly Sales (US$ Million), 2019
  • Figure 8-1: US - Trikafta FDA Approval History by Mutation
  • Figure 8-2: Trikafta/Kaftrio - Initial Approval Year by Region
  • Figure 8-3: Europe - Kaftrio Approval & Patent Expiration Year
  • Figure 8-4: US - Trikafta Approval & Patent Expiration Year
  • Figure 8-5: US - Trikafta Patent Approval & Expiration Year
  • Figure 8-6: US - Cost of Supply of 84 Oral Tablet & Per Unit Cost of Trikafta Oral Tablet (US$), May'2022
  • Figure 8-7: Europe - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (Euro/US$), May'2022
  • Figure 8-8: UK - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (GBP/US$), May'2022
  • Figure 8-9: Trikafta/Kaftrio - Recommended Initial & Reduced Dose (mg/day)
  • Figure 8-10: Global - Trikafta/Kaftrio Sales (US$ Million), Q1'2021 & Q1'2022
  • Figure 8-11: Global - Trikafta/Kaftrio Annual Sales (US$ Million), 2019 - 2021
  • Figure 8-12: Global - Trikafta/Kaftrio Quarterly Sales (US$ Million), 2021
  • Figure 8-13: Global - Trikafta/Kaftrio Quarterly Sales (US$ Million), 2020
  • Figure 9-1: Global - CFTR Modulators in Clinical Pipeline by Country, 2022 till 2028
  • Figure 9-2: Global - CFTR Modulators in Clinical Pipeline by Company, 2022 till 2028
  • Figure 9-3: Global - CFTR Modulators in Clinical Pipeline by Patient Segment, 2022 till 2028
  • Figure 9-4: Global - CFTR Modulators in Clinical Pipeline by Phase, 2022 till 2028
  • Figure 12-1: CFTR Modulator Market Favorable Parameters
  • Figure 12-2: Global - CFTR Modulator Annual Sales by Product (US$ Million), 2020
  • Figure 12-3: US - CFTR Modulator Annual WAC by Product (US$)
  • Figure 12-4: Stages of Drug Development
目次

“Global CFTR Modulators Market Opportunity, Drug Sales & Clinical Trials Insight 2028” Report Insight:

  • Global CFTR Modulators Market Opportunity: > USD 25 Billion
  • Global CFTR Modulators Market Insights: Current, Regional and Future Outlook 2028
  • Annual, Quarterly and Regional Sales Insights On CFTR Modulators
  • CFTR Modulators Availability By Dosage, Patent, and Price Analysis
  • Clinical Insight On More Than 30 CFTR Modulators In Trials
  • CFTR Modulators Clinical Trials Insight By Country, Company & Phase: > 30 Drugs

The approval of first CF transmembrane conductance regulator (CFTR) modulator has changed the face of cystic fibrosis in the era of precision medicine. Cystic fibrosis is a rare, life-shortening genetic disease caused by mutations of the cystic fibrosis transmembrane conductance regulator - or CFTR - gene. These modulators are designed to correct the malfunctioning protein made by the CFTR gene. This drug class has grown considerably from 2012, up to four agents available in the global market. Kalydeco was the first approved CFTR modulatory drug which has shown robust response in the market by significantly increasing the median survival rates in patients. The complexity of the disease has surged the development of several combinational therapies which have the ability to better tackle the complex nature of the disease. To overcome this, Orkambi, Symdeko, and Trikafta have been approved which belong to the class of CFTR combinational drugs. Currently, the market is dominated by combinational drugs owing to their enhanced efficacy in the management of disease and ability to overcome limitations of monotherapy.

The encouraging response of CFTR modulators in the market has led to further research and development activities in this domain. Several promising compounds are currently being evaluated which can be proven to be alternate to VX-770 to overcome gating mutations. Vertex pharmaceutical is conducting clinical trial on VX-561 (also called deutivacaftor) which an analogue of VX-770 in which one of the tert-butyl groups was replaced by a per-deuterated one. The preclinical data has demonstrated that the drug has similar activity as VX-770; however it has enhanced stability suggesting it could be prescribed once daily only, contrary to VX-770, which must be administered every 12 hours. The company is also developing another corrector, VX-121, which has reached clinical phase 3. It is being assessed in combination with VX-661, VX-770, and/or VX-56.

Although CFTR modulators have shown to dominate the cystic fibrosis treatment market, but there are still several challenges which need to be overcome. The currently available CFTR modulators drugs are target the underlying cause of cystic fibrosis. However, some patients with rare CFTR mutations are still ineligible to receive currently marketed therapies. Therefore, the opportunity remains for developers to investigate CFTR modulators for less common mutations. In addition, resistance against these drugs is another challenge which needs to be overcome.

As per our analysis, the global CFTR modulator market is expected to surpass US$ 25 Billion by 2028. The increasing prevalence and increasing funding from several nonprofit organizations including, Cystic Fibrosis Foundation, Cystic Fibrosis Worldwide, South African Cystic Fibrosis Trust, and South African Cystic Fibrosis Association, will drive the market growth but also encourages the research and development activities in cystic fibrosis. These organizations are investing huge amount of funds to find various CFTR modulators for cystic fibrosis and to support the research and developmental activities by prominent players. Further, robust clinical pipeline of drugs which will gain approval during forecast period will also boost the growth of market.

Our report "Global CFTR Modulators Market Opportunity, Drug Sales & Clinical Trials Insight 2028" enables the key stakeholders about the major trends, drivers, investments, and government initiatives toward the disease treatment. The report also provides comprehensive details of the existing pure-play companies and new players entering the market with key drugs in research and development. Moreover, the report provides insights about the major challenges that are going to hamper the market growth during the forecast period. Additionally, report provides information on the globally approved CFTR modulators along with their patent, price, dosage, and sales analysis till Q1 2022.

Table of Contents

1. Introduction to CFTR Modulators

  • 1.1. Overview
  • 1.2. Evolution of CFTR Modulators
  • 1.3. CFTR Modulators Mechanism of Action

2. Global CFTR Modulator Market Overview

  • 2.1. Current Market Scenario
  • 2.2. Future Market Potential of CFTR Modulators

3. US CFTR Modulator Market Overview

  • 3.1. Current Market Scenario
  • 3.2. Future Market Potential of CFTR Modulators

4. ROW CFTR Modulator Market Overview

  • 4.1. Current Market Scenario
  • 4.2. Future Market Potential of CFTR Modulators

5. Ivacaftor (Kalydeco) - Clinical & Commercial Insight

  • 5.1. Overview
  • 5.2. Patents & Assignees
  • 5.3. Price & Dosage Insight
  • 5.4. Sales Analysis

6. Ivacaftor/Lumacaftor (Orkambi) - Clinical & Commercial Insight

  • 6.1. Overview
  • 6.2. Patents & Assignees
  • 6.3. Price & Dosage Insight
  • 6.4. Sales Analysis

7. Tezacaftor/Ivacaftor (Symdeko) - Clinical & Commercial Insight

  • 7.1. Overview
  • 7.2. Patent & Assignees
  • 7.3. Price & Dosage Insight
  • 7.4. Sales

8. Elexacaftor/Ivacaftor/Tezacaftor (Trikafta) - Clinical & Commercial Insight

  • 8.1. Overview
  • 8.2. Patent & Assignees
  • 8.3. Price & Dosage Insight
  • 8.4. Global Sales

9. Global CFTR Modulators Clinical Pipeline Overview

  • 9.1. By Country
  • 9.2. By Company
  • 9.3. By Patient Segment
  • 9.4. By Phase

10. Global CFTR Modulators Clinical Trials Insight

  • 10.1. Research
  • 10.2. Preclinical
  • 10.3. Phase-I
  • 10.4. Phase-I/II
  • 10.5. Phase-II
  • 10.6. Phase-III

11. Marketed CFTR Modulators Clinical Insights

12. CFTR Modulator Drugs Market Dynamics

  • 12.1. Favorable Parameters
  • 12.2. Market Restraints

13. CFTR Modulator Market Future Perspective

14. Competitive Landscape

  • 14.1. Vertex Pharmaceuticals
  • 14.2. Eloxx Pharma
  • 14.3. ReCode Therapeutics
  • 14.4. Arcturus Therapeutics
  • 14.5. AbbVie
  • 14.6. Spirovant Sciences
  • 14.7. Translate Bio
  • 14.8. ReAlta Life Sciences
  • 14.9. Southern Research Institute
  • 14.10. 4D Molecular Therapeutics